Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
In the latest session, BioNTech SE ADR (NASDAQ: BNTX) closed at $96.73 up 0.65% from its previous closing price of $96.11. In other words, the price has increased by $0.65 from its previous closing price. On the day, 3.48 million shares were traded. BNTX stock price reached its highest trading level at $98.2 during the session, while it also had its lowest trading level at $96.2.
Ratios:
For a deeper understanding of BioNTech SE ADR’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.02 and its Current Ratio is at 7.12. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In the most recent recommendation for this company, H.C. Wainwright on June 05, 2025, Reiterated its Buy rating but revised its target price to $145 from $134 previously.
On May 29, 2025, Goldman started tracking the stock assigning a Neutral rating and target price of $110.
On March 13, 2025, Citigroup started tracking the stock assigning a Buy rating and target price of $145.Citigroup initiated its Buy rating on March 13, 2025, with a $145 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 28 ’25 when Tureci Ozlem bought 123,331 shares for $102.70 per share.
Medine GmbH bought 1,114,130 shares of BNTX for $124,448,321 on Nov 13 ’25. On Nov 05 ’25, another insider, Jeggle Helmut Wolfgang, who serves as the Director of the company, bought 150,000 shares for $103.43 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BNTX now has a Market Capitalization of 23259256832 and an Enterprise Value of 8977055744. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.58 while its Price-to-Book (P/B) ratio in mrq is 1.07. Its current Enterprise Value per Revenue stands at 2.848 whereas that against EBITDA is -19.19.
Stock Price History:
The Beta on a monthly basis for BNTX is 1.40, which has changed by -0.19126558 over the last 52 weeks, in comparison to a change of 0.12415576 over the same period for the S&P500. Over the past 52 weeks, BNTX has reached a high of $129.27, while it has fallen to a 52-week low of $81.20. The 50-Day Moving Average of the stock is -6.00%, while the 200-Day Moving Average is calculated to be -7.00%.
Shares Statistics:
For the past three months, BNTX has traded an average of 974.68K shares per day and 1239190 over the past ten days. A total of 240.46M shares are outstanding, with a floating share count of 238.79M. Insiders hold about 0.69% of the company’s shares, while institutions hold 21.45% stake in the company. Shares short for BNTX as of 1763078400 were 6025486 with a Short Ratio of 6.18, compared to 1760486400 on 6184865. Therefore, it implies a Short% of Shares Outstanding of 6025486 and a Short% of Float of 6.52.
Earnings Estimates
Its stock is currently analyzed by 13.0 different market analysts. The consensus estimate for the next quarter is -$2.03, with high estimates of -$1.39 and low estimates of -$3.89.
Analysts are recommending an EPS of between -$0.52 and -$5.57 for the fiscal current year, implying an average EPS of -$3.27. EPS for the following year is -$2.47, with 17.0 analysts recommending between $1.48 and -$8.71.
Revenue Estimates
A total of 10 analysts believe the company’s revenue will be $823.11M this quarter.It ranges from a high estimate of $1.4B to a low estimate of $659M. As of. The current estimate, BioNTech SE ADR’s year-ago sales were $1.19BFor the next quarter, 10 analysts are estimating revenue of $219.2M. There is a high estimate of $284.9M for the next quarter, whereas the lowest estimate is $153.5M.
A total of 17 analysts have provided revenue estimates for BNTX’s current fiscal year. The highest revenue estimate was $3.36B, while the lowest revenue estimate was $1.61B, resulting in an average revenue estimate of $2.69B. In the same quarter a year ago, actual revenue was $2.75BBased on 16 analysts’ estimates, the company’s revenue will be $2.61B in the next fiscal year. The high estimate is $3.35B and the low estimate is $1.58B.
